Superworth

Bausch & Lomb BLCO

Medical - Instruments & Supplies, Healthcare
$20.01
+0.05%
Market cap
$7.1B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
1.3×
EV/EBIT
33.9×
Revenue, 12 months
$5.3B
+9% on a year ago
Net margin
−3.2%
Free cash flow yield
1.9%

Bausch & Lomb trades at 1.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $5.3B over the last twelve months, up 9% on a year earlier with a −3% net margin.

Charts

Financials

Income statement for BLCO, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$1B+7%$1.2B+18%$1.1B+18%$1.2B+18%$1.2B+19%$1.3B+9%$1.1B+4%$1.3B+5%$1.3B+7%$1.4B+10%$1.2B+9%$1.4B+9%
Cost of revenue$392M+5%$461M+10%$424M+14%$483M+16%$464M+18%$501M+9%$482M+14%$525M+9%$510M+10%$533M+6%$483M+0%$527M+0%
Gross profit$615M+8%$712M+24%$675M+21%$733M+19%$732M+19%$779M+9%$655M−3%$753M+3%$771M+5%$872M+12%$761M+16%$867M+15%
R&D$82M+7%$80M+3%$82M+7%$84M−1%$84M+2%$93M+16%$86M+5%$96M+14%$95M+13%$94M+1%$101M+17%$114M+19%
SG&A$418M+10%$483M+25%$504M+21%$535M+28%$511M+22%$532M+10%$563M+12%$579M+8%$528M+3%$564M+6%$544M−3%$588M+2%
$40M−13%$49M−4%$6M$26M−40%$43M+8%$87M+78%−$83M−$11M$95M+121%$112M+29%$33M$83M
Interest expense$76M+117%$99M+111%$99M+98%$102M+76%$100M+32%$98M−1%$94M−5%$128M+26%$101M+1%$98M+0%$97M+3%$93M−27%
Pre-tax income−$35M−$57M+2750%−$90M+64%−$76M+300%−$58M+66%−$10M−83%−$180M+100%−$147M+93%−$3M−95%$13M−$64M−64%−$11M−93%
$45M+32%−$6M+200%$73M+121%$72M+620%−$66M−$8M+33%$31M−58%−$89M$22M$71M$6M−81%−$1M−99%
Net income−$84M+367%−$54M+5300%−$167M+86%−$151M+372%$4M−$3M−94%−$212M+27%−$62M−59%−$28M−$58M+1833%−$71M−67%−$14M−77%
−$0.24+380%−$0.15−$0.48+85%−$0.43+378%$0.01−$0.01−93%−$0.60+25%−$0.18−58%−$0.08−$0.16+1500%−$0.20−67%−$0.04−78%
350.8M+0%350.8M+0%351.1M+0%351.8M+0%353.9M+1%352.1M+0%352.8M+1%353.7M+1%354.2M+0%354.4M+1%355.2M+1%357.1M+1%

Gross profit: 22 periods, Q1 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Bausch & Lomb's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
BLCOBausch & Lomb$7.1Bn/mn/a1.3×+9%−3.2%
MSAMSA Safety$7.2B23.2×36.2×3.7×+6%16.1%
HAEHaemonetics$5.5B58.9×51.6×4.0×+0%7.1%
MMSIMerit Medical Systems$5.1B31.7×57.3×3.1×+9%9.9%
VNTVontier$5B15.3×13.5×1.6×+1%11.3%
PODDInsulet$10.7B28.7×62.7×3.5×+29%12.3%
GMEDGlobus Medical$10.7B20.3×37.4×3.4×+20%17.0%
ALGNAlign Technology$10.9B26.8×43.3×2.6×+4%10.0%
BMIBadger Meter$4.5B36.4×47.6×5.1×−2%14.4%
COOCooper Companies$11.7B20.9×40.2×2.8×+5%13.5%
ICUIICU Medical$4.1B138×57.9×1.9×−9%1.4%
Peer median$6.3B27.8×45.4×3.3×+5%11.8%

More on Bausch & Lomb

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .